VVOS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Vivos Therapeutics Inc (VVOS) is not a strong buy at this time for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock shows bearish technical indicators, weak financial performance, and lacks positive catalysts or strong trading signals. It is advisable to hold off on investing until the company demonstrates improved financial stability and operational efficiency.
The technical indicators are bearish. The MACD is negatively expanding below zero, the RSI is neutral at 27.349, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support levels are at 0.889 and 0.72, with resistance at 1.163 and 1.438. The stock is currently trading below key support levels in pre-market, with a pre-market price of 0.871 (-2.78%).
NULL identified. No recent news or significant positive developments. Analysts are cautiously optimistic about operational efficiency improving in 2026, but this is speculative.
Analysts have lowered price targets significantly, citing weak Q4 results, revenue misses, and higher expenses. The company may face share dilution to fund operations and service debt. No recent insider or hedge fund buying activity. Technical indicators are bearish.
In Q4 2025, revenue increased by 3.41% YoY to $3,824,000, but net income remains negative at -$6,894,000, albeit improving by 143.86% YoY. EPS improved to -0.49 (+25.64% YoY), but the company is still unprofitable. Gross margin dropped slightly to 52.38% (-0.81% YoY). Overall, financial performance remains weak.
H.C. Wainwright lowered the price target to $2.50 from $7, maintaining a Buy rating but expressing concerns about share dilution and financial stability. Alliance Global lowered the price target to $1.75 from $2.50, maintaining a Neutral rating due to weak Q4 results and potential balance sheet risks. Analysts are cautious, with no strong bullish sentiment.
